Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts)

MLA

Emily Piccione, et al. “Glofitamab Step-up Dosing (SUD): Complete Response Rates in Updated Efficacy Data in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts).” Journal of Clinical Oncology, vol. 39, May 2021, p. 7519. EBSCOhost, https://doi.org/10.1200/jco.2021.39.15_suppl.7519.

APA

Emily Piccione, Michael Dickinson, Emma Clark, Corinne Haioun, Gloria Iacoboni, Martin Hutchings, Emmanuel Bachy, Carmelo Carlo-Stella, Franck Morschhauser, David Perez-Callejo, Michael Crump, James Relf, Anna Sureda Balari, Anton Belousov, David Carlile, Kathryn Humphrey, Linda Lundberg, & Fritz Offner. (2021). Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). Journal of Clinical Oncology, 39, 7519. https://doi.org/10.1200/jco.2021.39.15_suppl.7519

Chicago

Emily Piccione, Michael Dickinson, Emma Clark, Corinne Haioun, Gloria Iacoboni, Martin Hutchings, Emmanuel Bachy, et al. 2021. “Glofitamab Step-up Dosing (SUD): Complete Response Rates in Updated Efficacy Data in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts).” Journal of Clinical Oncology 39 (May): 7519. doi:10.1200/jco.2021.39.15_suppl.7519.